M Amador

M Amador

Auto-generated profile, based on publicly available information

M Amador

MIT Portugal Program, International Risk Governance Council Portugal, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2015 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
KOKa Oye
Ka Oye
GJG Jain
G Jain
MAM Amador
M Amador
RAR Arnaout
R Arnaout
JBJs Brown
Js Brown
GHG Hirsch
G Hirsch
Beneath most lively policy debates sit dry-as-dust theoretical and methodological discussions. Current disputes over the EU Adaptive Pathways initiative and the proposed US 21st Century Cures Act may ultimately rest on addressing arcane issues of data curation, standardization, and utilization. Improved extraction of inform ation on the safety and effectiveness of drugs-in-use must parallel adjustments in evidence requirements at the time of licensing. To do otherwise may compromise safety and efficacy in the name of fostering innovation